Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03134638 · ClinicalTrials.gov registry record · Phase 1
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Syros Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT03134638: Clinical Trial Phase 1 study, sponsored by Syros Pharmaceuticals.
NCT03134638 is a Phase 1 study that was terminated before completion, run by Syros Pharmaceuticals. The registered enrollment target is 107 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03134638, a Phase 1 study, was terminated before completion, sponsored by Syros Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2. Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology.
Interventions
- DRUG Carboplatin
- DRUG Fulvestrant
- DRUG SY-1365 (Part 1)
- DRUG SY-1365 (Cohort 2)
- DRUG SY-1365 (Cohort 5)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-05-12 |
| Est. Completion | 2020-06-24 |
| Phase | Phase 1 |
Why NCT03134638 stopped before completion
NCT03134638 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% higher).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03134638 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03134638 about?
NCT03134638 is a clinical study titled "A Study of SY-1365 in Adult Patients With Advanced Solid Tumors". This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2. Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety a...
What is the current status of trial NCT03134638?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2017-05-12. Estimated completion is 2020-06-24.
What interventions are being tested in trial NCT03134638?
The interventions under investigation include: Carboplatin (DRUG), Fulvestrant (DRUG), SY-1365 (Part 1) (DRUG), SY-1365 (Cohort 2) (DRUG), SY-1365 (Cohort 5) (DRUG).
Who is sponsoring clinical trial NCT03134638?
This trial is sponsored by Syros Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03134638's enrollment target sits among peer trials
107 531st of 2000 higher than 1,470 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI